Phaseline

Targets › THPO

THPO (Thrombopoietin): drug programs, companies and trials

6 programs from 6 companies in 7 trials: 3 Phase 1, 2 Phase 2, 2 Phase 3; Hematology, Other; next expected readout Jan 2028.

Lineage-specific cytokine affecting the proliferation and maturation of megakaryocytes from their committed progenitor cells. It acts at a late stage of megakaryocyte development. (UniProt, P40225)

Open in Phaseline: the race on THPO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GeropharmGP40141
Thrombopoietin receptor agonist
THPOPhase 3Drug EffectMar 2028
MIBIO PTE.rhTPO
Recombinant human thrombopoietin (TPO) receptor agonist
THPOPhase 3Thrombocytopenia Associated With Chronic Liver DiseaseOct 2028
The First Affiliated Hospital of Soochow UniversityRecombinant Human Thrombopoietin
Recombinant thrombopoietin cytokine that binds to and activates the TPO receptor on megaka
THPOPhase 2MDS (Myelodysplastic Syndrome)Jan 2028
Anhui Provincial HospitalRecombinant human thrombopoietin
Thrombopoietin (TPO) analog
THPOPhase 2Thrombocytopenia–
Chongqing Peg-Bio BiopharmPN20
thrombopoietin receptor agonist
THPOPhase 1Primary Immune Thrombocytopenia (ITP); Thrombocytopenia Associated With Chronic Liver Disease–
Sichuan Clover BiopharmaceuticalsSCB-219M
TNF receptor II-Fc fusion protein with TPO mimetic peptide
TNFRSF1B, THPOPhase 1Chemotherapy-induced Thrombocytopenia (CIT)–

Conditions

Thrombocytopenia Associated With Chronic Liver Disease (2) MDS (Myelodysplastic Syndrome) (1) Drug Effect (1) Thrombocytopenia (1) Chemotherapy-induced Thrombocytopenia (CIT) (1) Primary Immune Thrombocytopenia (ITP) (1)

Modalities

small molecule (5), protein or peptide (1)

Companies

The First Affiliated Hospital of Soochow University (1) Geropharm (1) MIBIO PTE. (1) Anhui Provincial Hospital (1) Sichuan Clover Biopharmaceuticals (1) Chongqing Peg-Bio Biopharm (1)

Related targets

TNFRSF1B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.